Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Imunon Inc IMNN

Healthcare Biotechnology
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment... see more

Recent & Breaking News (NDAQ:IMNN)

First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial

GlobeNewswire June 5, 2024

Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

GlobeNewswire May 15, 2024

IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

GlobeNewswire May 13, 2024

IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 13, 2024

IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

GlobeNewswire May 8, 2024

IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024

GlobeNewswire May 6, 2024

IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101

GlobeNewswire April 18, 2024

IMUNON Reports Compliance with Nasdaq Listing Requirements

GlobeNewswire April 11, 2024

IMUNON Reports 2023 Financial Results and Provides Business Update

GlobeNewswire March 28, 2024

IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses

GlobeNewswire March 25, 2024

IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024

GlobeNewswire March 21, 2024

IMUNON Files IND Application to Begin Human Testing of IMNN-101

GlobeNewswire March 13, 2024

IMUNON Announces Leadership Change

GlobeNewswire March 12, 2024

Independent Lab Confirms Immunogenicity and Protection with IMUNON's IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5

GlobeNewswire February 29, 2024

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON's IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

GlobeNewswire February 27, 2024

IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine

GlobeNewswire February 22, 2024

IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 11, 2023

IMUNON's VP of R&D to Present at the Vaccines Summit-2023

GlobeNewswire November 14, 2023

IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update

GlobeNewswire November 14, 2023

IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023

GlobeNewswire November 7, 2023